Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
- Filed IND with the FDA for AT342 in Crigler-Najjar Syndrome - Large Scale Internal cGMP Manufacturing Capability Expected to be Established for Entire Pipeline of Four Programs - Preliminary Clinical Data from Lead Programs Expected by Year-End SAN FRANCISCO , Jan.
Toggle Summary Audentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO , Jan. 4, 2017 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics Appoints Julie Anne Smith to Board of Directors
SAN FRANCISCO , Dec. 13, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the appointment of Julie Anne Smith
Toggle Summary Audentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
Milestone Establishes Audentes as a Leader in AAV Gene Therapy Manufacturing SAN FRANCISCO , Nov. 29, 2016 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious,
Toggle Summary Audentes Therapeutics to Attend Piper Jaffray 28th Annual Healthcare Conference
SAN FRANCISCO , Nov. 21, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced its plans to attend the Piper Jaffray
Toggle Summary Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility, Commenced Enrollment in the INCEPTUS Clinical Assessment Study of XLMTM SAN FRANCISCO , Nov. 10, 2016 /PRNewswire/ --  Audentes Therapeutics,
Toggle Summary Audentes Therapeutics to Present at Upcoming Investor Conferences
SAN FRANCISCO , Sept. 21, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Achievements Included Completion of IPO, Initiation of Large Scale Manufacturing Runs and Enrollment of First Patient in a Clinical Assessment Study of XLMTM SAN FRANCISCO , Aug. 31, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on
Toggle Summary Audentes Therapeutics Announces First Patient Enrolled in the INCEPTUS Clinical Assessment Study of XLMTM
Study intended to serve as longitudinal baseline and within-patient control for ASPIRO, the planned Phase 1 / 2 study of AT132 for the treatment of XLMTM SAN FRANCISCO , Aug. 17, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused
Toggle Summary Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO, Calif. , Aug. 8, 2016 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases, today announced that Matthew R.